Le Lézard
Classified in: Health
Subject: OFR

Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering



ENGLEWOOD, Colo., Oct. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio") today announced that it has closed it's previously announced registered direct offering of 7,709,400 shares of common stock at a purchase price of $0.875 per share for gross proceeds of approximately $6.75 million.

Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio intends to use the net proceeds from this offering for working capital and general corporate purposes, including funding of the Ampiontm clinical trial.

Joseph Gunnar & Co., LLC, and Fordham Financial Management, Inc. acted as placement agents for the offering.

The sale of the common stock was offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A final prospectus supplement was filed with the SEC and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained by contacting Joseph Gunnar & Co., LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: prospectus@jgunnar.com or Fordham Financial Management, Inc. at: 17 Battery Place, Suite 643, New York, NY 10004, by telephone at: 212-732-8500, or by email at: Compliance@FordhamFinancial.com.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.

About Ampio Pharmaceuticals: 

Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Investor Contact:
Tom Chilcott
Chief Financial Officer
Phone: (720) 437-6500
tchilcott@ampiopharma.com

Forward-Looking Statements:
This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the proposed registered direct offering of Ampio's common stock. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ are discussed in the risks and uncertainties detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

 

SOURCE Ampio Pharmaceuticals, Inc.


These press releases may also interest you

at 22:00
LOS ANGELES, April 24, 2018 /PRNewswire-PRWeb/ -- An April 3 article on Reuters reports on a Swedish study regarding the impact of weight loss procedures on marriages and relationships. The study found that the rate of new marriages or relationships...

at 20:54
PTC Therapeutics, Inc. today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing FIREFISH clinical trial. The open-label trial is evaluating RG7916, an oral survival motor neuron 2 (SMN2) splicing...

at 20:41
Beleave Inc. ("Beleave" or the "Company") is pleased to announce its intention to complete a non-brokered private placement (the "Non-Brokered Offering") of up to 2,857,143 units of the Company at a price of $1.75 per unit for gross proceeds of...

at 20:30
The Personalized Lifestyle Medicine Institute (PLMI) will host the Sixth Annual Thought Leaders Consortium Oct. 12-13, 2018 at the Westin La Paloma Resort and Spa in Tucson, Arizona. The title of the 2018 conference is The Science of Precision:...

at 19:36
Suzanne R. Grady, DDS is recognized by Continental Who's Who as New York's Most Trusted Pediatric Dentist in the field of Pediatric Dentistry in recognition of her role at Open Sesame Dentistry. Located in Upper West Side, New York, Open Sesame...

at 19:36
Eric Adam Heller, M.D., M.S., FACC, FSCAI, FSVM, is recognized by Continental Who's Who as a Pinnacle Lifetime Member in the field of Medicine in recognition of his role as Cardiologist at Florida Premiere Cardiology.     Florida Premiere...




News published on 18 october 2017 at 22:30 and distributed by: